Prevalence of cognitive impairment in patients with substance use disorder
Introduction and Aims Cognitive impairments in substance use disorder predict treatment outcome and are assumed to differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cognitive functioning across substances by means of a cogniti...
Gespeichert in:
| Veröffentlicht in: | Drug and alcohol review 2019-05, Vol.38 (4), p.435-442 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 442 |
|---|---|
| container_issue | 4 |
| container_start_page | 435 |
| container_title | Drug and alcohol review |
| container_volume | 38 |
| creator | Bruijnen, Carolien J. W. H. Dijkstra, Boukje A. G. Walvoort, Serge J. W. Markus, Wiebren VanDerNagel, Joanne E. L. Kessels, Roy P. C. DE Jong, Cornelis A. J. |
| description | Introduction and Aims
Cognitive impairments in substance use disorder predict treatment outcome and are assumed to differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cognitive functioning across substances by means of a cognitive screen at the early stage of addiction treatment.
Design and Methods
The Montreal Cognitive Assessment was administered to outpatients seeking treatment for substance use disorder. Patient characteristics (age, years of regular use, polysubstance use, severity of dependence/abuse, depression, anxiety and stress) were also taken into account.
Results
A total of 656 patients were included (n = 391 used alcohol, n = 123 used cannabis, n = 100 used stimulants and n = 26 used opioids). The prevalence of cognitive impairments was 31%. Patients using alcohol had a lower total‐ and memory domain score than those using cannabis. Patients using opioids scored lower on visuospatial abilities than those using cannabis or stimulants. Younger patients scored higher than older patients. No effect was found for the other investigated characteristics.
Discussion and Conclusions
Given the high prevalence of cognitive impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group, and more research is needed on the effect of age on Montreal Cognitive Assessment performance. |
| doi_str_mv | 10.1111/dar.12922 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6593747</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2221737825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4432-b4c7a2c67954c1939f5fd7cce55cd5f7d16519be6fff1212eeb789081c9809003</originalsourceid><addsrcrecordid>eNp1kFtLwzAYhoMobh4u_ANS8MqLbjk0TXMjjHlmoIhehzRNtoyunUm7sX9vZufQC3PzBfJ8T15eAC4QHKBwhoV0A4Q5xgegj5KUxoSk-BD0Iac8ppikPXDi_RxCiCnFx6BHIEdpkmR98Pzq9EqWulI6qk2k6mllG7vSkV0spXULXTWRraKlbGy4-mhtm1nk29w3crvSeh0V1teu0O4MHBlZen2-m6fg4_7uffwYT14ensajSayShOA4TxSTWKWM00QhTrihpmBKaUpVQQ0rUEoRz3VqjEEYYa1zlnGYIcUzyCEkp-Cm8y7bfKELFXI5WYqlswvpNqKWVvx9qexMTOuVSCknLGFBcLUTuPqz1b4R87p1VcgsMMaIEZZhGqjrjlKu9t5ps_8BQbGtXYTaxXftgb38HWlP_vQcgGEHrG2pN_-bxO3orVN-AZGEjX4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2221737825</pqid></control><display><type>article</type><title>Prevalence of cognitive impairment in patients with substance use disorder</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Bruijnen, Carolien J. W. H. ; Dijkstra, Boukje A. G. ; Walvoort, Serge J. W. ; Markus, Wiebren ; VanDerNagel, Joanne E. L. ; Kessels, Roy P. C. ; DE Jong, Cornelis A. J.</creator><creatorcontrib>Bruijnen, Carolien J. W. H. ; Dijkstra, Boukje A. G. ; Walvoort, Serge J. W. ; Markus, Wiebren ; VanDerNagel, Joanne E. L. ; Kessels, Roy P. C. ; DE Jong, Cornelis A. J.</creatorcontrib><description>Introduction and Aims
Cognitive impairments in substance use disorder predict treatment outcome and are assumed to differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cognitive functioning across substances by means of a cognitive screen at the early stage of addiction treatment.
Design and Methods
The Montreal Cognitive Assessment was administered to outpatients seeking treatment for substance use disorder. Patient characteristics (age, years of regular use, polysubstance use, severity of dependence/abuse, depression, anxiety and stress) were also taken into account.
Results
A total of 656 patients were included (n = 391 used alcohol, n = 123 used cannabis, n = 100 used stimulants and n = 26 used opioids). The prevalence of cognitive impairments was 31%. Patients using alcohol had a lower total‐ and memory domain score than those using cannabis. Patients using opioids scored lower on visuospatial abilities than those using cannabis or stimulants. Younger patients scored higher than older patients. No effect was found for the other investigated characteristics.
Discussion and Conclusions
Given the high prevalence of cognitive impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group, and more research is needed on the effect of age on Montreal Cognitive Assessment performance.</description><identifier>ISSN: 0959-5236</identifier><identifier>EISSN: 1465-3362</identifier><identifier>DOI: 10.1111/dar.12922</identifier><identifier>PMID: 30916448</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Addictions ; Adolescent ; Adult ; Aged ; Alcohol ; Alcoholism - epidemiology ; Analgesics, Opioid ; Anxiety ; Cognition & reasoning ; Cognitive Dysfunction - epidemiology ; Cognitive functioning ; Cognitive impairment ; Cross-Sectional Studies ; Drug abuse ; Drug use ; Female ; Health services utilization ; Help seeking behavior ; Humans ; Intoxication ; Male ; Marijuana ; Marijuana Abuse - epidemiology ; Medical screening ; Medical treatment ; Mental depression ; Middle Aged ; Montreal cognitive assessment ; Multiple drugs ; Narcotics ; Opioids ; Original Paper ; Original Papers ; Outpatients ; Prevalence ; Severity ; Stimulants ; Substance abuse ; Substance use disorder ; Substance-Related Disorders - epidemiology ; Treatment needs ; Young Adult</subject><ispartof>Drug and alcohol review, 2019-05, Vol.38 (4), p.435-442</ispartof><rights>2019 The Authors Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs</rights><rights>2019 The Authors Drug and Alcohol Review published by John Wiley & Sons Australia, Ltd on behalf of Australasian Professional Society on Alcohol and other Drugs.</rights><rights>2019 Australasian Professional Society on Alcohol and other Drugs (APSAD)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4432-b4c7a2c67954c1939f5fd7cce55cd5f7d16519be6fff1212eeb789081c9809003</citedby><cites>FETCH-LOGICAL-c4432-b4c7a2c67954c1939f5fd7cce55cd5f7d16519be6fff1212eeb789081c9809003</cites><orcidid>0000-0003-1467-7808 ; 0000-0002-7641-9890 ; 0000-0003-1824-7303 ; 0000-0001-5316-6299 ; 0000-0002-3857-0303 ; 0000-0001-9500-9793 ; 0000-0002-4133-3165</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdar.12922$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdar.12922$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,30976,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30916448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bruijnen, Carolien J. W. H.</creatorcontrib><creatorcontrib>Dijkstra, Boukje A. G.</creatorcontrib><creatorcontrib>Walvoort, Serge J. W.</creatorcontrib><creatorcontrib>Markus, Wiebren</creatorcontrib><creatorcontrib> VanDerNagel, Joanne E. L.</creatorcontrib><creatorcontrib>Kessels, Roy P. C.</creatorcontrib><creatorcontrib>DE Jong, Cornelis A. J.</creatorcontrib><title>Prevalence of cognitive impairment in patients with substance use disorder</title><title>Drug and alcohol review</title><addtitle>Drug Alcohol Rev</addtitle><description>Introduction and Aims
Cognitive impairments in substance use disorder predict treatment outcome and are assumed to differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cognitive functioning across substances by means of a cognitive screen at the early stage of addiction treatment.
Design and Methods
The Montreal Cognitive Assessment was administered to outpatients seeking treatment for substance use disorder. Patient characteristics (age, years of regular use, polysubstance use, severity of dependence/abuse, depression, anxiety and stress) were also taken into account.
Results
A total of 656 patients were included (n = 391 used alcohol, n = 123 used cannabis, n = 100 used stimulants and n = 26 used opioids). The prevalence of cognitive impairments was 31%. Patients using alcohol had a lower total‐ and memory domain score than those using cannabis. Patients using opioids scored lower on visuospatial abilities than those using cannabis or stimulants. Younger patients scored higher than older patients. No effect was found for the other investigated characteristics.
Discussion and Conclusions
Given the high prevalence of cognitive impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group, and more research is needed on the effect of age on Montreal Cognitive Assessment performance.</description><subject>Addictions</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Alcohol</subject><subject>Alcoholism - epidemiology</subject><subject>Analgesics, Opioid</subject><subject>Anxiety</subject><subject>Cognition & reasoning</subject><subject>Cognitive Dysfunction - epidemiology</subject><subject>Cognitive functioning</subject><subject>Cognitive impairment</subject><subject>Cross-Sectional Studies</subject><subject>Drug abuse</subject><subject>Drug use</subject><subject>Female</subject><subject>Health services utilization</subject><subject>Help seeking behavior</subject><subject>Humans</subject><subject>Intoxication</subject><subject>Male</subject><subject>Marijuana</subject><subject>Marijuana Abuse - epidemiology</subject><subject>Medical screening</subject><subject>Medical treatment</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Montreal cognitive assessment</subject><subject>Multiple drugs</subject><subject>Narcotics</subject><subject>Opioids</subject><subject>Original Paper</subject><subject>Original Papers</subject><subject>Outpatients</subject><subject>Prevalence</subject><subject>Severity</subject><subject>Stimulants</subject><subject>Substance abuse</subject><subject>Substance use disorder</subject><subject>Substance-Related Disorders - epidemiology</subject><subject>Treatment needs</subject><subject>Young Adult</subject><issn>0959-5236</issn><issn>1465-3362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNp1kFtLwzAYhoMobh4u_ANS8MqLbjk0TXMjjHlmoIhehzRNtoyunUm7sX9vZufQC3PzBfJ8T15eAC4QHKBwhoV0A4Q5xgegj5KUxoSk-BD0Iac8ppikPXDi_RxCiCnFx6BHIEdpkmR98Pzq9EqWulI6qk2k6mllG7vSkV0spXULXTWRraKlbGy4-mhtm1nk29w3crvSeh0V1teu0O4MHBlZen2-m6fg4_7uffwYT14ensajSayShOA4TxSTWKWM00QhTrihpmBKaUpVQQ0rUEoRz3VqjEEYYa1zlnGYIcUzyCEkp-Cm8y7bfKELFXI5WYqlswvpNqKWVvx9qexMTOuVSCknLGFBcLUTuPqz1b4R87p1VcgsMMaIEZZhGqjrjlKu9t5ps_8BQbGtXYTaxXftgb38HWlP_vQcgGEHrG2pN_-bxO3orVN-AZGEjX4</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Bruijnen, Carolien J. W. H.</creator><creator>Dijkstra, Boukje A. G.</creator><creator>Walvoort, Serge J. W.</creator><creator>Markus, Wiebren</creator><creator> VanDerNagel, Joanne E. L.</creator><creator>Kessels, Roy P. C.</creator><creator>DE Jong, Cornelis A. J.</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1467-7808</orcidid><orcidid>https://orcid.org/0000-0002-7641-9890</orcidid><orcidid>https://orcid.org/0000-0003-1824-7303</orcidid><orcidid>https://orcid.org/0000-0001-5316-6299</orcidid><orcidid>https://orcid.org/0000-0002-3857-0303</orcidid><orcidid>https://orcid.org/0000-0001-9500-9793</orcidid><orcidid>https://orcid.org/0000-0002-4133-3165</orcidid></search><sort><creationdate>201905</creationdate><title>Prevalence of cognitive impairment in patients with substance use disorder</title><author>Bruijnen, Carolien J. W. H. ; Dijkstra, Boukje A. G. ; Walvoort, Serge J. W. ; Markus, Wiebren ; VanDerNagel, Joanne E. L. ; Kessels, Roy P. C. ; DE Jong, Cornelis A. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4432-b4c7a2c67954c1939f5fd7cce55cd5f7d16519be6fff1212eeb789081c9809003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Addictions</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Alcohol</topic><topic>Alcoholism - epidemiology</topic><topic>Analgesics, Opioid</topic><topic>Anxiety</topic><topic>Cognition & reasoning</topic><topic>Cognitive Dysfunction - epidemiology</topic><topic>Cognitive functioning</topic><topic>Cognitive impairment</topic><topic>Cross-Sectional Studies</topic><topic>Drug abuse</topic><topic>Drug use</topic><topic>Female</topic><topic>Health services utilization</topic><topic>Help seeking behavior</topic><topic>Humans</topic><topic>Intoxication</topic><topic>Male</topic><topic>Marijuana</topic><topic>Marijuana Abuse - epidemiology</topic><topic>Medical screening</topic><topic>Medical treatment</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Montreal cognitive assessment</topic><topic>Multiple drugs</topic><topic>Narcotics</topic><topic>Opioids</topic><topic>Original Paper</topic><topic>Original Papers</topic><topic>Outpatients</topic><topic>Prevalence</topic><topic>Severity</topic><topic>Stimulants</topic><topic>Substance abuse</topic><topic>Substance use disorder</topic><topic>Substance-Related Disorders - epidemiology</topic><topic>Treatment needs</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bruijnen, Carolien J. W. H.</creatorcontrib><creatorcontrib>Dijkstra, Boukje A. G.</creatorcontrib><creatorcontrib>Walvoort, Serge J. W.</creatorcontrib><creatorcontrib>Markus, Wiebren</creatorcontrib><creatorcontrib> VanDerNagel, Joanne E. L.</creatorcontrib><creatorcontrib>Kessels, Roy P. C.</creatorcontrib><creatorcontrib>DE Jong, Cornelis A. J.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Drug and alcohol review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bruijnen, Carolien J. W. H.</au><au>Dijkstra, Boukje A. G.</au><au>Walvoort, Serge J. W.</au><au>Markus, Wiebren</au><au> VanDerNagel, Joanne E. L.</au><au>Kessels, Roy P. C.</au><au>DE Jong, Cornelis A. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of cognitive impairment in patients with substance use disorder</atitle><jtitle>Drug and alcohol review</jtitle><addtitle>Drug Alcohol Rev</addtitle><date>2019-05</date><risdate>2019</risdate><volume>38</volume><issue>4</issue><spage>435</spage><epage>442</epage><pages>435-442</pages><issn>0959-5236</issn><eissn>1465-3362</eissn><abstract>Introduction and Aims
Cognitive impairments in substance use disorder predict treatment outcome and are assumed to differ between substances. They often go undetected, thus the current study focuses on the prevalence of and differences in cognitive functioning across substances by means of a cognitive screen at the early stage of addiction treatment.
Design and Methods
The Montreal Cognitive Assessment was administered to outpatients seeking treatment for substance use disorder. Patient characteristics (age, years of regular use, polysubstance use, severity of dependence/abuse, depression, anxiety and stress) were also taken into account.
Results
A total of 656 patients were included (n = 391 used alcohol, n = 123 used cannabis, n = 100 used stimulants and n = 26 used opioids). The prevalence of cognitive impairments was 31%. Patients using alcohol had a lower total‐ and memory domain score than those using cannabis. Patients using opioids scored lower on visuospatial abilities than those using cannabis or stimulants. Younger patients scored higher than older patients. No effect was found for the other investigated characteristics.
Discussion and Conclusions
Given the high prevalence of cognitive impairments, standard screening at an early stage of treatment is important to determine the course of treatment and maximise treatment outcome. Caution is needed in interpreting results about opioids due to an underrepresentation of this patient group, and more research is needed on the effect of age on Montreal Cognitive Assessment performance.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>30916448</pmid><doi>10.1111/dar.12922</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1467-7808</orcidid><orcidid>https://orcid.org/0000-0002-7641-9890</orcidid><orcidid>https://orcid.org/0000-0003-1824-7303</orcidid><orcidid>https://orcid.org/0000-0001-5316-6299</orcidid><orcidid>https://orcid.org/0000-0002-3857-0303</orcidid><orcidid>https://orcid.org/0000-0001-9500-9793</orcidid><orcidid>https://orcid.org/0000-0002-4133-3165</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-5236 |
| ispartof | Drug and alcohol review, 2019-05, Vol.38 (4), p.435-442 |
| issn | 0959-5236 1465-3362 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6593747 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Addictions Adolescent Adult Aged Alcohol Alcoholism - epidemiology Analgesics, Opioid Anxiety Cognition & reasoning Cognitive Dysfunction - epidemiology Cognitive functioning Cognitive impairment Cross-Sectional Studies Drug abuse Drug use Female Health services utilization Help seeking behavior Humans Intoxication Male Marijuana Marijuana Abuse - epidemiology Medical screening Medical treatment Mental depression Middle Aged Montreal cognitive assessment Multiple drugs Narcotics Opioids Original Paper Original Papers Outpatients Prevalence Severity Stimulants Substance abuse Substance use disorder Substance-Related Disorders - epidemiology Treatment needs Young Adult |
| title | Prevalence of cognitive impairment in patients with substance use disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A35%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20cognitive%20impairment%20in%20patients%20with%20substance%20use%20disorder&rft.jtitle=Drug%20and%20alcohol%20review&rft.au=Bruijnen,%20Carolien%20J.%20W.%20H.&rft.date=2019-05&rft.volume=38&rft.issue=4&rft.spage=435&rft.epage=442&rft.pages=435-442&rft.issn=0959-5236&rft.eissn=1465-3362&rft_id=info:doi/10.1111/dar.12922&rft_dat=%3Cproquest_pubme%3E2221737825%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2221737825&rft_id=info:pmid/30916448&rfr_iscdi=true |